[{"orgOrder":0,"company":"Elite Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Elite Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Elite Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Elite Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Elite Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Methotrexate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Elite Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Elite Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Elite Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Elite Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Paracetamol","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Elite Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Elite Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Elite Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Elite Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Acetaminophen & codeine phosphate is a pain relief medicine. It is approved for use in adults for relief of mild to moderate pain & the management of moderate to severe pain.

                          Brand Name : Tylenol-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 09, 2024

                          Lead Product(s) : Paracetamol,Codeine Phosphate

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Methotrexate sodium is a DHFR inhibitor small molecule drug candidate, has been approved for the treatment of acute lymphoblastic leukemia in adults.

                          Brand Name : Methotrexate Sodium-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 20, 2024

                          Lead Product(s) : Methotrexate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Central nervous stimulant is a generic version of an undisclosed product which is being evaluated in preclinical studies for the treatment of neurological disorders.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          December 26, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank